Inex's Marqibo to get ODAC review

Inex (TSX:IEX) and partner Enzon (ENZN) said that on Dec. 1, FDA's Oncologic Drugs Advisory Committee will review an NDA for Marqibo (formerly Onco TCS) to treat relapsed, aggressive non-Hodgkin's lym...